20920-98-3

Usage

Uses

Used in Pharmaceutical Industry:
6-methoxy-3,4-dihydro-2H-chromen-2-one is used as a pharmacological agent for its anti-inflammatory properties, helping to reduce inflammation and alleviate pain in various conditions.
Used in Cancer Therapy:
In the field of oncology, 6-methoxy-3,4-dihydro-2H-chromen-2-one is used as a potential anti-cancer agent, exhibiting the ability to inhibit tumor growth and induce cell death in cancer cells, making it a promising candidate for future cancer treatments.
Used in Cardiovascular Health:
6-methoxy-3,4-dihydro-2H-chromen-2-one is used as a cardiovascular protective agent, contributing to the maintenance of cardiovascular health through its antioxidant properties and its ability to protect against oxidative stress.
Used in Traditional Medicine:
In traditional medicine, 6-methoxy-3,4-dihydro-2H-chromen-2-one is used as an analgesic and anti-inflammatory agent, providing relief from pain and reducing inflammation in various ailments.
Used in Antioxidant Formulations:
6-methoxy-3,4-dihydro-2H-chromen-2-one is used as an antioxidant in various formulations, including dietary supplements and skincare products, to protect cells from oxidative damage and promote overall health.

Upstream product

• 150-76-5 4-methoxy-phenol 
• 140-88-5 ethyl acrylate 
• 87823-55-0 methoxy-6 diethoxy-2,2 benzopyranne-1 
• 5111-70-6 5-methoxy-1-indanone 
• 10026-13-8 phosphorus pentachloride 
• 20811-60-3 3-(4-methoxyphenoxy)propanoic acid 
• 71-43-2 benzene 
• 17372-53-1 6-methoxycoumarin 
• 33538-99-7 2-hydroxy-5-methoxycinnamaldehyde 

Downstream Products

• 20921-09-9 ethyl 3-(2-hydroxy-5-methoxyphenyl)propionate 
• 225791-33-3 2-hydroxy-5-methoxybenzenepropanoic acid 
• 1323994-60-0 (2S,R(S))-6-methoxy-2-[(p-tolylsulfinyl)methyl]chroman 
• 1323994-62-2 (2R,R(S))-6-methoxy-2-[(p-tolylsulfinyl)methyl]chroman 
• 1323994-13-3 (R(S))-6-methoxy-2-[(p-tolylsulfinyl)methyl]chroman-2-ol 
• 1323994-17-7 C₁₈H₂₀O₄S 
• 736985-86-7 2-hydroxy-6-methoxychroman 
• 1360546-21-9 (E)-ethyl 3-(2-(3-(dibenzylamino)-3-thioxopropyl)-4-methoxyphenyl)acrylate 
• 1360546-31-1 ethyl 2-((1S,2R)-2-(dibenzylcarbamothioyl)-5-methoxy-2,3-dihydro-1H-inden-1-yl)acetate 
• 33538-88-4 3-(2',5'-dimethoxyphenyl)propanal 
• 33538-81-7 3-(2,5-Dimethoxyphenyl)propanol 
• 33538-76-0 5-Methoxy-2-hydroxyhydrozimtalkohol 

Relevant academic research and scientific papers

Organocatalyst-Mediated Dynamic Kinetic Enantioselective Acylation of 2-Chromanols

We recently developed a novel chiral catalyst-directed dynamic kinetic diastereoselective acylation of hemiacetals for the synthesis of carbohydrates. In this update, we describe a catalytic method for the dynamic kinetic enantioselective acylation of 2-c

Substituted 2 - (chroman - 6 - yloxy) thiazole and use thereof as a medicament

The invention relates to a substitutional-2-(chroman-6-oxyl) thiazole shown as a formula I, wherein Ar, R2, R3 and R4 are defined in claims. The compound shown as the formula I is a sodium-calcium permutoid (NCX) inhibitor, especially a sodium-calcium permutoid subtype 1 (NCX1) inhibitor, and is applicable to treatment of various disorders caused by calcium unbalance in cells, such as arrhythmia, cardiac failure and apoplexy. The invention also relates to a method for preparing the compound shown as the formula I, an application of the compound as the medicine and a medicine composition containing the compound.

Substd. 2 - (chromane-6-carbonoyloxysilane) and its use as medicine iminothiazole-

PROBLEM TO BE SOLVED: To provide: a compound usable for disorders such as arrhythmia, cardiac failure and cerebral apoplexy caused by disturbance of intracellular calcium homeostasis of sodium-calcium exchanger (NCX), especially sodium-calcium exchanger of subtype 1 (NCX1); production method of the compound; use thereof as a pharmaceutical; and a pharmaceutical composition including the compound.SOLUTION: There is disclosed a substituted 2-(chroman-6-yloxy)-thiazole compound expressed by general formula I.

Investigation of cationic Claisen-type electrophilic rearrangements of amides

Abstract Herein we report an extension of the electrophilic rearrangement of amides to the preparation of α-prenyl-hydrocoumarins, indoles, isoquinolines and dihydro-isoquinolinones. An unusual competitive sulfonyl migration, uncovered upon attempted aza-

Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals

Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1 ), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula (I), in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

Stereoselective synthesis of 2H-chromans by reductive deoxygenation of differently substituted 2-sulfinylmethylchroman-2-ols

Good-to-excellent diastereoselectivies have been achieved in the synthesis of 2H-chromans by Et3SiH/TMSOTf reductive deoxygenation of differently substituted 2-sulfinylmethylchroman-2-ols and their methyl ketals. The influence of both electron-

Enzymatic Baeyer-Villiger oxidation of Benzo-Fused ketones: Formation of regiocomplementary lactones

Baeyer-Villiger monooxygenases (BVMOs) are enzymes that are known to catalyse the Baeyer-Villiger oxidation of ketones in aqueous media using O2 as oxidant. Herein, we describe the oxidation of a set of diverse benzo-fused ketones by three different BVMOs